These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2006-001358-29 A Phase 2 Study of ARQ 501 in Combination with Gemcitabine in Adult Patients with Treatment Naive, Unresectable Pancreatic Adenocarcinoma 2008-08-15 due-trials
Not reported 2006-001942-15 A Phase 2 Study of ARQ 501 in Patients with Locally Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck 2008-05-05 due-trials
Completed, but no date, and reported results Terminated 2007-002727-32 A Randomized Phase 2 Study of ARQ 197 versus Gemcitabine in Treatment-naïve Patients with Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma bad-data
Not reported Terminated 2007-004622-25 A Randomized Phase 2 Study of ARQ 197 versus Investigator’s Choice of Second-Line Chemotherapy in Patients with Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Fo... 2008-11-07 due-trials
Reported results 2007-004634-17 A Randomized Phase 2 Study of Erlotinib plus ARQ 197 versus Erlotinib plus Placebo in Previously Treated Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer 2011-05-19 due-trials
Reported results 2008-007155-27 A Randomized Controlled Phase 2 Trial of ARQ 197 in Patients with Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy 2012-04-18 due-trials
Reported results 2009-011669-10 A Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Associated Tumors 2010-12-17 due-trials
Ongoing 2010-020151-31 An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols not-yet-due
Exempt 2015-001443-36 A Phase 1/2 Study of ARQ 087 in Adult Subjects with Advanced Solid Tumors with FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma with FGFR2 not-yet-due
Exempt 2016-000558-37 A Phase 1/2 Study of ARQ 092 in Patients with Overgrowth Diseases and Vascular Anomalies with Genetic Alterations of the PI3K/AKT Pathway not-yet-due
Ongoing 2016-004448-12 A pivotal study of derazantinib in patients with inoperable or advanced intrahepatic cholangiocarcinoma and FGFR2 gene fusions or FGFR2 gene mutations or amplifications not-yet-due